A Dark Vector Cognition product

Item 6. EXHIBITS

7K characters. Original on sec.gov ·

Item 6. EXHIBITS

NumberDescription
3.1Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 29, 2022).
3.2Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 29, 2022).
10.1Credit Agreement, dated as of February 26, 2026, among the Registrant, as the borrower, JPMorgan Chase Bank, N.A., as the Administrative Agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed with the SEC on February 27, 2026).
10.2Amendment No. 1, dated as of February 26, 2026, to the Credit Agreement dated as of March 27, 2025, among the Registrant, each lender party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent.
10.3Offer Letter with Jeannette Bankes, dated November 15, 2024.†
10.42026 GE HealthCare Restricted Stock Unit Grant Agreement.
10.52026 GE HealthCare Stock Option Grant Agreement.
10.62026 GE HealthCare Performance Stock Unit Grant Agreement.
10.72026 GE HealthCare New Hire Restricted Stock Unit Grant Agreement.
10.82026 Global Addendum.
31.1Certification of the Registrant’s Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of the Registrant’s Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certifications of the Registrant’s Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101The following materials from GE HealthCare Technologies Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in inline XBRL (eXtensible Business Reporting Language); (1) Condensed Consolidated Statements of Income for the three months ended March 31, 2026 and 2025; (2) Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2026 and 2025; (3) Condensed Consolidated Statements of Financial Position as of March 31, 2026 and December 31, 2025; (4) Condensed Consolidated Statements of Changes in Equity for the three months ended March 31, 2026 and 2025; (5) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025; and (6) Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
†Certain portions of this exhibit have been redacted pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K, as applicable. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GE HealthCare Technologies Inc.
(Registrant)
April 29, 2026/s/ George A. Newcomb
DateGeorge A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)

Previous: Item 5. OTHER INFORMATION